• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Model-based Clinical Efficacy Prediction and Study Design Support for VIS410, a Novel Neutralizing mAb, in Combination with Oseltamivir, in Hospitalized Patients with Influenza A

February 23, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Xiong, et. al.

Model-based Clinical Efficacy Prediction and Study Design Support for VIS410, a Novel Neutralizing mAb, in Combination with Oseltamivir, in Hospitalized Patients with Influenza A

Yuan Xiong, Mark Lovern, Patrick Smith, Russell Wada, Susan Sloan, Ellie Hershberger

>SEE POSTER

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design